Ovid Therapeutics Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Ovid Therapeutics Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-03-31 was $220.00K, a 1592.31% increase year-over-year.
- Ovid Therapeutics Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $15.00K, a 59.46% decline year-over-year.
- Ovid Therapeutics Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Ovid Therapeutics Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-03-31 was $13.00K, a 94.30% decline year-over-year.
- Ovid Therapeutics Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $91.00K, a 85.37% decline from fiscal 2024.
- Ovid Therapeutics Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $622.00K, a 16.26% increase from fiscal 2023.
- Ovid Therapeutics Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $535.00K, a 196.14% increase from fiscal 2022.
- Ovid Therapeutics Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $180.66K, a 80.48% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-03-31 | $220.00K 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $91.00K 10-K · filed 2026-03-18 | |
| 2025-09-30 | $15.00K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $0.00 10-Q · filed 2025-11-12 | |
| 2025-03-31 | $13.00K 10-Q · filed 2026-05-12 | |
| 2024-12-31 | $622.00K 10-K · filed 2026-03-18 | |
| 2024-09-30 | $37.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $356.00K 10-Q · filed 2025-11-12 | |
| 2024-03-31 | $228.00K 10-Q · filed 2025-11-12 | |
| 2023-12-31 | $535.00K 10-K · filed 2025-03-11 | |
| 2023-09-30 | $224.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $211.00K 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $67.00K 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $180.66K 10-K · filed 2024-03-08 | |
| 2022-09-30 | $81.63K 10-Q · filed 2023-11-03 | |
| 2022-06-30 | $109.55K 10-Q · filed 2023-11-03 | |
| 2022-03-31 | $33.08K 10-Q · filed 2023-11-03 | |
| 2021-12-31 | $925.74K 10-K · filed 2023-03-13 | |
| 2021-09-30 | $74.50K 10-Q · filed 2021-11-10 | |
| 2021-03-31 | $130.17K 10-Q · filed 2022-08-09 | |
| 2020-12-31 | $203.47K 10-K · filed 2022-03-15 | |
| 2020-09-30 | $120.36K 10-Q · filed 2021-11-10 | |
| 2020-03-31 | $83.11K 10-Q · filed 2021-11-10 | |
| 2019-12-31 | $131.90K 10-K · filed 2021-03-15 | |
| 2019-09-30 | $58.79K 10-Q · filed 2020-11-13 | |
| 2019-03-31 | $73.10K 10-Q · filed 2020-11-13 | |
| 2018-12-31 | $174.76K 10-K · filed 2020-03-11 | |
| 2018-09-30 | $112.04K 10-Q · filed 2019-11-08 | |
| 2018-03-31 | $62.72K 10-Q · filed 2019-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |